larotrectinib

High Alert

Solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic, or are likely to result in severe morbidity with surgical resection, and have either progressed following treatment or have no satisfactory alternative therapy.

Action ⬆ ⬇

Acts as an inhibitor of the tropomyosin receptor tyrosine kinases (encoded by the NTRK genes), which ultimately inhibits growth of cancer cell lines.

Therapeutic effects:

Decreased spread of certain solid tumors.

Pharmacokinetics ⬆ ⬇

Absorption: 34% absorbed following oral administration; absorption ↓ with high-fat meals.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver by the CYP3A4 isoenzyme. 58% excreted in feces (5% as unchanged drug), 39% excreted in urine (20% as unchanged drug).

Half-Life: 2.9 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	1 hr	12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Moderate or severe hepatic impairment (↓ dose);
Rep: Women of reproductive potential and men with female partners of reproductive potential.

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension, peripheral edema

EENT: nasal congestion

GI: abdominal pain, constipation, diarrhea, hypoalbuminemia, hepatotoxicity, ↑liver enzymes, nausea, vomiting

GU: dehydration, ↓fertility

Hemat: anemia, neutropenia

Metab: ↓appetite, ↑weight

MS: arthralgia, muscle weakness, myalgia

Neuro: dizziness, falls, fatigue, headache, delirium, dysarthria, gait disturbance, memory impairment, paresthesia, tremor

Resp: cough, dyspnea

Misc: fever

Interactions ⬆ ⬇

Drug-drug:

Strong CYP3A4 inhibitors, including itraconazole, may significantly ↑ levels; avoid concurrent use; if need to use strong CYP3A4 inhibitor, ↓ larotrectinib dose.
Strong CYP3A4 inducers, including rifampin, may significantly ↓ levels; avoid concurrent use; if need to use strong CYP3A4 inducer, double larotrectinib dose.
Strong CYP3A4 inducers, including efavirenz, may ↓ levels; double larotrectinib dose.
May ↑ levels of CYP3A4 substrates; avoid concurrent use with CYP3A4 substrates with a narrow therapeutic index.

Drug-Natural Products:

St. John's wort may significantly ↓ levels; avoid concurrent use.

Drug-Food:

Grapefruit juice may significantly ↑ levels; avoid concurrent use.

Route/Dosage ⬆ ⬇

PO (Adults and Children with BSA ≥1 m²): 100 mg twice daily until disease progression or unacceptable toxicity. Concurrent use of strong CYP3A4 inhibitor: 50 mg twice daily until disease progression or unacceptable toxicity. Concurrent use of strong or moderate CYP3A4 inducer: 200 mg twice daily until disease progression or unacceptable toxicity.
PO (Children with BSA <1 m²): 100 mg/m² twice daily until disease progression or unacceptable toxicity. Concurrent use of strong CYP3A4 inhibitor: 50 mg/m² twice daily until disease progression or unacceptable toxicity. Concurrent use of strong or moderate CYP3A4 inducer: 200 mg/m² twice daily until disease progression or unacceptable toxicity.

Hepatic Impairment

(Adults and Children with BSA ≥1 m²): Moderate to severe hepatic impairment: 50 mg twice daily until disease progression or unacceptable toxicity.

Hepatic Impairment

(Children with BSA <1 m²): Moderate to severe hepatic impairment: 50 mg/m² twice daily until disease progression or unacceptable toxicity.

Availability ⬆ ⬇

Capsules: 25 mg; 100 mg
Oral solution: 20 mg/mL

Assessment ⬆ ⬇

Assess for signs and symptoms of neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paresthesia, memory impairment, tremor) periodically during therapy. Usually occur during first 3 mo of therapy.

Lab Test Considerations:

Patient selection is based on presence of a NTRK gene fusion in tumor specimens. Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics.
- Verify negative pregnancy test before starting therapy.
- Monitor ALT and AST at baseline, then every 2 wk during 1st mo of therapy, then monthly and as clinically indicated. If ALT or AST ≥5 times upper limit of normal (ULN) with total bilirubin ≤2 times ULN, hold larotrectinib until recovery to ≤Grade 1 or baseline. Resume at next lower dose level. Permanently discontinue larotrectinib if Grade 4 ALT and/or ALT elevation occurs after resuming therapy. If ALT or AST >3 times ULN with total bilirubin >2 times ULN with no alternative cause, permanently discontinue larotrectinib.
- May cause hypoalbuminemia and ↑ alkaline phosphatase.
- May cause anemia and neutropenia.

Implementation ⬆ ⬇

For Grade 3 or 4 adverse reactions (other than hepatotoxicity), hold larotrectinib until improves to baseline or Grade 1. Resume at next lower dose if resolved within 4 wk. If no resolution within 4 wk, permanently discontinue.
Dose modification schedule: First dose reduction (adults and children with BSA ≥1 m²⁾: 75 mg twice daily. First dose reduction (children with BSA <1 m²⁾: 75 mg/m² twice daily. Second dose reduction (adults and children with BSA ≥1 m²⁾: 50 mg twice daily. Second dose reduction (children with BSA <1 m²⁾: 50 mg/m² twice daily. Third dose reduction (adults and children with BSA ≥1 m²⁾: 100 mg once daily. Third dose reduction (children with BSA <1 m²⁾: 25 mg/m² twice daily. If unable to tolerate after dose reductions, discontinue permanently.
PO: Administer twice daily without regard to food. DNC: Swallow capsules whole; do not open, break, or chew. Oral solutions and capsule are interchangeable. Store oral solution in refrigerator; do not freeze. Discard unused solution 90 days after opening bottle.

Patient/Family Teaching ⬆ ⬇

Instruct patient to take larotrectinib as directed. If vomiting occurs after dose, omit dose and take next dose at scheduled time. Take missed doses as soon as remembered up to 6 hr before next dose. Do not change dose or stop taking larotrectinib without consulting health care professional. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
Advise patient to avoid grapefruit juice during therapy.
Caution patient that larotrectinib may cause dizziness. Advise patient to avoid driving or other activities requiring alertness until response to drug is known.
Advise patient to notify health care professional if signs and symptoms of new or worsening neurotoxicity (confusion; difficulty speaking; dizziness; coordination problems; tingling, numbness, or burning sensation in hands and feet) or liver problems (loss of appetite, nausea or vomiting, pain on upper right side of stomach) occur.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's wort.
Rep: May cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception and to avoid breastfeeding during and for 1 wk after last dose. May impair female fertility.
Emphasize importance of regular lab tests to monitor for side effects.

Evaluation/Desired Outcomes ⬆ ⬇

Decreased tumor spread.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

17337- Olon S.p.A.
- 17337-0317-
  - 17337-0317-1- 1 BAG in 1 DRUM (17337-0317-1) / 1 BAG in 1 BAG / 20 kg in 1 BAG

17337- Olon S.p.A.
- 17337-0324-
  - 17337-0324-1- 1 BAG in 1 DRUM (17337-0324-1) / 1 BAG in 1 BAG / 20 kg in 1 BAG

22568- W. R. Grace & Co.-Conn.
- 22568-1752-
  - 22568-1752-1- 5 kg in 1 DRUM (22568-1752-1)

50419- Bayer HealthCare Pharmaceuticals Inc.
- 50419-390- VITRAKVI
  50419-390-01- 60 CAPSULE in 1 BOTTLE (50419-390-01)

50419- Bayer HealthCare Pharmaceuticals Inc.
- 50419-391- VITRAKVI
  - 50419-391-01- 60 CAPSULE in 1 BOTTLE (50419-391-01)

50419- Bayer HealthCare Pharmaceuticals Inc.
- 50419-392- VITRAKVI
  - 50419-392-01- 100 mL in 1 BOTTLE (50419-392-01)

50419- Bayer HealthCare Pharmaceuticals Inc.
- 50419-393- VITRAKVI
  - 50419-393-03- 2 BOTTLE in 1 CARTON (50419-393-03) / 50 mL in 1 BOTTLE (50419-393-02)

63069- Penn Pharmaceutical Services Limited
- 63069-390-
  - 63069-390-01- 60 CAPSULE in 1 BOTTLE (63069-390-01)

63069- Penn Pharmaceutical Services Limited
- 63069-391-
  63069-391-01- 60 CAPSULE in 1 BOTTLE (63069-391-01)

63069- Penn Pharmaceutical Services Limited
- 63069-392-
  63069-392-01- 100 mL in 1 BOTTLE (63069-392-01)

71777- Loxo Oncology, Inc.
- 71777-390- VITRAKVI
  71777-390-01- 60 CAPSULE in 1 BOTTLE (71777-390-01)

71777- Loxo Oncology, Inc.
- 71777-391- VITRAKVI
  - 71777-391-01- 60 CAPSULE in 1 BOTTLE (71777-391-01)

71777- Loxo Oncology, Inc.
- 71777-392- VITRAKVI
  - 71777-392-01- 100 mL in 1 BOTTLE (71777-392-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇